ARK Genomic Revolution ETFARKG
Type
ETF
Peer group
US equity: Healthcare
Net assets
$1.2B
Expense ratio
0.75%
1-year return
+91.1%
3 years, a year
+13.6%
5 years, a year
-11.1%
12-month yield
0.00%
Holdings
33
What it aims to do.
The ARK Genomic Revolution ETFs (Fund) investment objective is long -term growth of capital.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| TEM Tempus Ai Inc | 9.42% |
| TWST Twist Bioscience Corp | 8.99% |
| JOBY Crispr Therapeutics Ag | 8.91% |
| TXG 10x Genomics Inc | 5.77% |
| BEAM Beam Therapeutics Inc | 5.43% |
| ABSI Absci Corp | 4.78% |
| NTRA Natera Inc | 4.07% |
| ILMN Illumina Inc | 4.03% |
| NTLA Intellia Therapeutics Inc | 3.82% |
| PSNL Personalis Inc | 3.58% |
More on ARKG.
- ARKG overview
- ARKG holdings
- ARKG risk
- ARKG costs
- ARKG money in and out
- ARKG share classes
- Compare ARKG with other funds
Returns after fees, from the fund's SEC filings up to Aug 2026. Past returns are not a promise. Not financial advice.